Universität zu Köln

Mallmann, Peter and Mallmann, Christoph (2016). Neoadjuvant and Adjuvant Chemotherapy of Cervical Cancer. Oncol. Res. Treat., 39 (9). S. 522 - 525. BASEL: KARGER. ISSN 2296-5262

Full text not available from this repository.

Abstract

Neoadjuvant chemotherapy is indicated in patients who can tolerate the side effects of a chemotherapy and with preoperative presentation of one of the following clinical risk situations: bulky disease with a maximal tumor diameter of > 4 cm, suspicious lymph nodes in magnetic resonance imaging (MRI), computed tomography (CT) scan or endosonography, histopathologically confirmed lymph node metastasis, or histopathologically documented risk factors such as G3 and L1V1. A neoadjuvant chemotherapy followed by surgery should be performed with cisplatin at a dosage of > 25 mg/m(2) per week and an application interval of < 14 days. The previously published data suggests an improved rate of complete resection and reduced incidences of positive lymph nodes and parametric infiltration. Accordingly, the percentage of patients in need for adjuvant radiochemotherapy after operation can be significantly reduced. Some studies demonstrated a prolongation of progression-free and overall survival. Following the previously published studies, adjuvant chemotherapy after operation or after radiochemotherapy has no significant effect on the overall survival and, following the current guidelines, should be avoided. (C) 2016 S. Karger GmbH, Freiburg

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Mallmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Mallmann, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-264826
DOI:	10.1159/000449023
Journal or Publication Title:	Oncol. Res. Treat.
Volume:	39
Number:	9
Page Range:	S. 522 - 525
Date:	2016
Publisher:	KARGER
Place of Publication:	BASEL
ISSN:	2296-5262
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language METAANALYSIS; BEVACIZUMAB; CARCINOMA; SURVIVAL; EFFICACY Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/26482